MedTrace Logo

Studies of White Blood Cells Derived From HHT Patients

NCT00230633 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-09-28

No results posted yet for this study

Summary

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study goal is to culture white blood cells that express the proteins mutated in HHT and examine in the laboratory to explain aspects of the HHT disease phenotype.

Conditions

  • Telangiectasia, Hereditary Hemorrhagic

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Claire L Shovlin · Imperial College London

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230633 on ClinicalTrials.gov